BofA raised the firm’s price target on Alkermes (ALKS) to $35 from $34 and keeps a Neutral rating on the shares. The firm’s higher target ...

整体上，通过氨基酸残基间的相互作用，多肽形成了特定的三维结构以识别并结合 OX2 受体。 作用机理及研究进展 作用机理：(Ala11,D-Leu15)-Orexin B 是一种高效且选择性的 OX2 受体激动剂，对 OX2 受体的选择性比对 OX1 受体高 400 倍 。当它与 OX2 受体结合后，会诱导 ...

Idorsia has become the first drugmaker in the EU to claim approval for a drug for chronic insomnia in the dual orexin receptor antagonist class, ahead of rival drugs from Merck & Co and Eisai.

Daridorexant, Idorsia’s dual orexin receptor antagonist, shows consistent efficacy across both insomnia- and nocturia-related endpoints in a placebo-controlled study in patients with chronic insomnia ...

Analysts have recently evaluated Harmony Biosciences Hldgs and provided 12-month price targets. The average target is $58.0, ...

Dr Leah Kaylor, a psychologist and sleep expert says: “Occasionally, more sleep may be required after emotionally intense ...

In a report released today, Jason Gerberry from Bank of America Securities maintained a Hold rating on Alkermes (ALKS – Research Report), with ...

Daridorexant, Idorsia's dual orexin receptor antagonist, shows consistent efficacy across both insomnia- and nocturia-related endpoints in a placebo-controlled study in patients with chronic insomnia ...

Daridorexant, a dual orexin receptor antagonist, is currently approved for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.

After hours: March 18 at 4:17:36 PM EDT Loading Chart for CNTA ...

Meanwhile, Johnson & Jonson's orexin 2 antagonist seltorexant, Intra-Cellular Therapies' serotonin 5-HT2a antagonist Caplyta (lumateperone), and Relmada Therapeutic' NMDA drug dextromethadone (REL ...